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Development of cytarabine prodrugs and delivery systems for
leukemia treatment
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Abstract
Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of
myeloid leukemia and non-Hodgkin’s lymphoma. The drug has a short plasma half-life,
low stability, and limited bioavailability. Overdosing of patients with continuous infusions
may lead to side effects. Thus, various prodrug strategies and delivery systems have
been extensively explored to enhance the half-life, stability, and delivery of cytarabine.
Among the recent cytarabine prodrugs, amino acid conjugate ValCytarabine and fatty
acid derivative CP-4055 (in phase 3 trials) have been investigated for the treatment of
leukemia and solid tumors, respectively. Alternatively, delivery systems of cytarabine
have emerged for the treatment of different cancers. The liposomal-cytarabine
formulation (DepoCyt®) has been approved for the treatment of lymphomatous
meningitis.
Areas covered in this review: Various prodrug strategies evaluated for cytarabine are
discussed. Then, the review summarizes the drug delivery systems that have been
used for more effective cancer therapy.
What reader will gain: This review provides in-depth discussion of the prodrug strategy
and delivery systems of cytarabine derivatives for the treatment of cancer. The design
of cytarabine prodrugs and delivery systems provide insights for designing the next
generation of more effective anticancer agents with enhanced delivery and stability.
Take home message: Strategies on designing cytarabine prodrug and delivery
formulations showed great promise in developing effective anticancer agents with better
therapeutic profile. Similar studies with other anticancer nucleosides can be an
alternative approach to gaining access to more effective anticancer agents.
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1. Introduction
Blood cancers such as leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and
myeloma are characterized by the abnormal production of malformed lymphocytes
and/or other blood cells. The cancer cells multiply without control and accumulate in
bone marrow, blood and lymphatic tissues, and thus interfere with healthy cells and
immune cell production and function. Ultimately these events result in blood/lymphatic
disorders, such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes
based on affected tissue [1].
The malformed cells are results of one or more acquired mutations in DNA of
lymphatic or blood forming stem cells, which on multiplication (clone formation)
generate high number of abnormal white blood cells. For example, in chronic
myelogenous leukemia (CML) acquired mutation affects hematopoietic stem cells. CML
is characterized by presence of Philadelphia (Ph) chromosome generated through
translocation and fusion of the Abelson oncogene (ABL) at chromosome 9 and the
break-point cluster region (BCR) at chromosome 22 leading to the generation of a BCRABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein [2].
Leukemia, lymphoma, and myeloma are diagnosed in all ages and account for the
deaths of approximately 54,000 people in United States in 2010, nearly 9.5 percent of
deaths from cancer in 2010. Leukemia is a one of the most fatal hematopoietic
neoplasms and represents a wide range of blood cancers mainly related to abnormal
increase in the number of white blood cells (leukocytes). The death toll is expected to
increase as new cases are diagnosed annually, suggesting a highly fatal nature of
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leukemia if unattended or untreated at early stages of development [3]. Thus, causes,
diagnosis, treatment, and prognosis of leukemia are subjects of major interest. [4].
Depending upon the type of abnormal early blast or mature cells present, leukemia
can be categorized into acute or chronic forms, respectively. The acute leukemia is
identified by the rapid increase of immature white blood cells that crowd and accumulate
around bone marrow, and thus induce the haemopoietic organ inability to produce
normal blood cells. Therefore, immediate and aggressive treatment is required in acute
leukemia due to rapid progression and accumulation of the malformed cells, which with
time, enter the bloodstream and invade other organs. Chronic leukemia is caused by
the excessive build up of abnormal mature white blood cells, which takes time to
progress [5]. Further, leukemia can be lymphoblastic or lymphocytic leukemias (LL) and
myeloid or myelogenous leukemias (ML) depending upon type of blood cell affected.
The lymphoblastic or lymphocytic leukemias occur due to the cancerous modifications
of bone marrow cells that are converted to lymphocytes. Lymphocytes have roles as the
infection-fighting immune system cells. The myeloid or myelogenous leukemias result
from the cancerous change of marrow cell that form red blood cells, platelets, and white
blood cells [6,7].
Owing to the heterogeneity of leukemia, treatment options for different classes of
leukemias vary. The leukemia chemotherapy involves drugs from different classes
ranging from kinase inhibitors to DNA synthesis inhibitors [8]. In many cases, a
combination of two or more drugs is administered to patients to manage leukemia
[9,10]. Radiotherapy is sometimes used along with chemotherapy in some types and
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stages of blood cancer, such as acute lymphocytic leukemia (ALL) and B-Cell
lymphomas [11,12].
Cytarabine (4-amino-1-β-D-arabinofuranosyl-2-(1H)-pyrimidinone, 1-β-Darabinofuranosylcytosine, araC, Cytosar-U) is a pyrimidine nucleoside-based anticancer
drug (Figure 1) with arabinose sugar widely used for the treatment of leukemia.
Cytarabine is predominantly used against acute myelogenous leukemia (AML) and nonHodgkin’s lymphoma (NHL), chronic myelocytic leukemia (blast phase), ALL and
erythroleukemia [13,14]. It may be used alone or in combination with other anticancer
agents, such as daunorubicin, doxorubicin, thioguanine, or vincristine.
When cytarabine is used in combination with other anticancer drugs for the
treatment of different leukemias and solid tumors [15,16], the drug combinations
generally improve the cancer therapy by synergistic effect [17]. Cytarabine is used in
induction therapy in combination with anthracyclines and in consolidation therapy at
higher dose for AML patients. The combination of cytarabine with purine nucleoside
analogs, such as fludarabine and cladribine, has been extensively explored in the
treatment of patients with relapsed or refractory AML [18]. In Hodgkin’s disease (HD)
and NHL, cytarabine is used in conjunction with other drugs using different regimens,
such as DHAP (cytarabine-cisplatin-dexamethasone) [19] and ESHAP (etoposidemethylprednisolone-cytarabine-cisplatin) [20] in patients with relapsed or refractory
lymphoma. Cytarabine is used as front line drug for mantle cell lymphoma (MCL) [21].
Hyyper CVAD-MTX/Ara-c regimen (rituximab with hyperfractioned cyclophosphamide,
doxorubicin, vincristine and dexamethasone plus methotrexate and cytarabine) is used
for Burkitt’s leukemia/lymphoma [22] and ALL [23].
6

Figure 1. Chemical structure of cytarabine.

Cytarabine acts on rapidly dividing cells and inhibits DNA synthesis at S-phase of
cell cycle and also hinders progression of cells from G1 phase to the S-phase. When
inside the cell, cytarabine is converted into the triphosphate derivatives by kinase
enzymes to show its cytotoxic effect. The exact mechanism of action of cytarabine
triphosphate has not been elucidated but it appears to inhibit DNA polymerase by
competing with deoxycytidine triphosphate [24] and thus reduces the cell replication.
Cytarabine is a polar nucleoside and has a short plasma half-life. After three
phosphorylation step, cytarabine is converted to cytarabine triphosphate. It has been
suggested that cytarabine triphosphate inhibits DNA polymerase by competing with the
natural substrate, deoxycytidine triphosphate, resulting in DNA synthesis inhibition. The
low bioavailability of cytarabine is created by its low permeability across cell membrane
and rapid conversion into inactive 1-β-D-arabinofuranosyluracil (AraU). The drug is
rapidly converted into its uridine derivative by deamination of cytosine ring in the
presence of cytidine deaminase [25]. Thus, continuous intravenous infusion of higher
doses is required to maintain constant plasma level of the drug in 8 to 24 h. The higher
7

doses of cytarabine lead to toxicity on normal organs and side effects [26]. Alternatively,
cytarabine is administered by subcutaneous infusion in which peak plasma levels are
attained after 20 to 60 min and decrease below steady-state level after 100 min [27].
Understanding the mechanism of the action and metabolism of cytarabine has
allowed many investigations to improve the low bioavailability and stability. These
efforts, depending upon formulation and modification, can be divided into two major
categories: prodrugs and drug delivery systems. The prodrug strategy for cytarabine
involves the chemical modification or introduction of a potentiating group on parent drug
while the delivery system involved in physical encapsulation of drug without introduction
of any chemical modification on parent drug. The molecules synthesized for prodrug
evaluation may have higher therapeutic effect while the delivery system may improve
the effect in a particular tissue or organ. Various explored prodrug strategies and
potential of delivery systems for cytarabine are discussed.

2. Cytarabine Prodrugs
Most of the therapeutic drugs have to pass physiological barriers before reaching
to the target organ/tissue of action. Many drugs get modified into inactive derivatives
during the transportation process. Among the various strategies used to minimize the
undesirable metabolism of drug, prodrug approach offers a great promise in retention of
pharmacological properties of drugs, improving the drug efficacy, decreasing the
toxicity, or reduction in dose of administration.
Prodrugs are defined as pharmacologically inert chemical derivatives that can be
converted into the active drug molecules under in vivo physiological conditions through
8

an enzymatically or nonenzymatic process, to exert a therapeutic effect at desired target
site. An Ideal prodrug is converted to the original therapeutically active form of drug at
target organ and the substituted group is eliminated from the body [28]. Thus, prodrug
approach may minimize undesirable toxicity related to the parent drug in non-targeted
organs [29, 30].
Many prodrugs have been developed to improve drug efficacy, absorption,
bioavailability, instability, drug delivery, drug specificity, toxicity, membrane
transportation, or patient adherence (like poor taste or odor of drug) [31,32]. Designing
of prodrugs generally depends upon many factors including the mechanism of action,
enzymatic interaction, lipophilicity, functional groups present on the drug and their
lability, and metabolic pathway of drug.
There have been major efforts on the development of cytarabine derivatives to
generate compounds with higher therapeutic index for the treatment of leukemia and
lymphoma (sections 2.1-2.3). Among the explored strategies, the prodrug strategy of
introducing modifications on the parent drug to enhance plasma half-life or delivery to
cancer cells is a subject of major interest.
The prodrug design for cytarabine has been explored on the basis of mechanism
of action and metabolism of the drug. The deamination of the cytosine base of
cytarabine by cytidine deaminase leads to formation of uridine derivative (AraU) and
deactivation of the drug. In general, cytarabine prodrugs have been designed either to
circumvent its catabolism into AraU or to enhance cellular delivery. Some of the prodrug
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approaches included designing amino acid-cytarabine, fatty acid-cytarabine, and amino
acid-fatty acid-cytarabine derivatives (sections 2.1 and 2.2).
Mechanistically, cytarabine acts as a prodrug itself and is converted
intracellularly to cytarabine triphosphate through monophosphate and diphosphate
derivatives before generating biological activities. In the process, monophosphorylation
is the rate-limiting step in the metabolic conversion to triphosphate form. Alternatively,
many phosphate derivatives of cytarabine have been evaluated as prodrugs to improve
the cellular uptake of active metabolites (section 2.3).

2.1 Amino acid derivatives
Many amino acid and peptide derivatives are known to increase the cellular
uptake of the drug molecules. Peptides with both nucleophilic group (-NH2) and
electrophilic (-COOH) groups can be used for the conjugation of a large number of drug
molecules. Amino acid or peptide attached to a drug can reduce the undesired
metabolism by modification of the hydrolytic activity or the steric effect surrounding
susceptible functional groups. Cytarabine derivatives substituted with amino acids at 4amino or 5′-hydroxyl positions have been synthesized and evaluated by different groups
as described below.
The amino acid-substituted derivatives of cytarabine at 4-amino position were
designed to reduce the metabolism of cytarabine into uridine derivative by blocking the
proximity of cytidine deaminase. Derivatization of cytarabine with a single amino acid at
amino group reported by Jin et al. [33] involved the protection of hydroxyl groups by tert10

butyldimethyl silyl (TBDMS) followed by the conjugation with protected amino acids.
Amino acid derivatives synthesized with arginine, leucine and isoleucine (Figure 2) were
evaluated for cellular uptake in Caco-2 cells and were compared with that of cytarabine.
The arginine derivative was shown to have comparable uptake while the leucine and
isoleucine derivatives reduced the uptake of drug. They have also compared the
concentration dependency cellular uptake of the synthesized derivatives and found a
similar uptake for cytarabine and arginine-cytarabine at increased concentrations while
leucine-cytarabine and isoleucine-cytarabine derivatives showed less cellular uptake
than that of the parent drug at higher concentrations.

Figure 2. N4-substituted amino acid derivatives of cytarabine.

Sun et al. reported the 5′-amino acid derivatives of cytarabine and compared
their cellular uptake in Caco-2 and HELA cells [34] (Figure 3). Among the various amino
acid derivatives, the 5′-valyl prodrug exhibited highest permeability across the Caco-2
cells monolayer followed by the 5′-isoleucine derivative. Compared to L-Isomer of
valine, D-isomer had significantly less cellular uptake, suggesting that the
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stereochemical oligopeptide transporters may be involved in transporting amino acid
prodrugs. Antiproliferative studies on the HL-60 cells showed the comparable activity of
amino acid derivatives versus that of parent cytarabine. The antiproliferative effects of
cytarabine and the amino acid ester prodrugs (IC50) in HL-60 Cells were reported as
cytarabine (20 µM), 5′-L-valyl-cytarabine (16 µM), 5′-D-valyl-cytarabine (20 µM), 5′-Lisoleucyl-cytarabine (21 µM), 5′-L-phenylalanyl-cytarabine (17 µM), 5′-D-phenylalanylcytarabine (16 µM), and 5′-L-tryptophyl-cytarabine (19 µM). The study recommended
the valyl prodrug as the potential candidate for the oral delivery of cytarabine in a similar
fashion the other valyl prodrugs that have been reported to be promising with other
nucleoside drugs for other conditions [35].

Figure 3. Structure of 5′-amino acid ester prodrugs.

2.2 Fatty acid derivatives
The pharmacological properties of drugs depend upon overall surface
interactions with medium and can be modulated by variation in the
12

lipophilicity/hydrophilicity ratio. The presence of long fatty acyl chains makes the drug
molecules lipophilic [36]. Furthermore, the lipophilic drugs pass across the membrane
rapidly and make the drug available for biological action at higher intracellular
concentration in target cells. The fatty acid conjugation of the drugs through
esterification or amidation leads to formation of ester or amide bond, respectively, with
the drug molecule. The approach has two advantages: First, the conjugation protects
the functional group. Second, the substitution allows sustained and continuous release
of the drug through hydrolysis thus minimizing the side effects at higher doses of drugs.
The prodrug approach using fatty acid derivatization at 5′-OH and 4-NH2 groups
of cytarabine has been evaluated by many research groups. In addition to making the
drug more lipophilic, the strategy may also allow the protection of cytarabine from
cytidine deaminase enzyme action and thus preventing its metabolism into inactive form
AraU.
Fatty acid presence along with amino acid further utilizes the assumed properties
of amino acid as well as fatty chains. Liu. et al. has used the advantage of simultaneous
amino acid and fatty acid derivatization [37]. They reported N4-amino acid (Val, Met,
Tyr, Glu and Arg) and fatty acid derivatives with chain length of 10, 14 and 18 carbons
(Figure 4). The synthesis was accomplished through the direct coupling of amino acidfatty acyls derivatives and cytarabine at 4-NH2 (i.e., N4) position through a peptide
bond. The synthesized derivatives showed variation in anti-proliferative activities with
different amino acids and/or fatty acid. The studies performed using HL-60 and HELA
cells showed potential reduction in IC50 with the substitution at N4. Among the different
amino acids derivatives, the methionine derivative demonstrated better antiproliferative
13

activity when compared to the other synthesized conjugates. The antiproliferative
activity was dependant on the chain length and decreased with increase in chain length
at N4, suggesting that introduction of bulky groups at N4 through amide bond would not
be beneficial in improving biological activity.

Figure 4. Structure of fatty acid-amino acid-cytarabine derivatives.

Fatty acids-substituted conjugates of cytarabine at 5′-OH showed significantly
different behavior than N4 derivatives. Derivatization with different saturated and
unsaturated higher fatty acids showed comparable activity to that of cytarabine in
different cell lines [38]. Among the derivatives, CP-4055, a fatty acid derivative of
cytarabine (ara-C-5′-elaidic acid ester) (Figure 5), facilitated and enhanced cellular
accumulation and retention of ara-C in tumor cells. Unlike cytarabine, the cellular uptake
of CP-4055 is independent of nucleoside transporters, and is believed to be via passive
diffusion through the cellular membrane or an alternative internalization mechanism
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[39]. CP-4055 is then hydrolyzed intracellularly by esterases to release free cytarabine,
which is subsequently phosphorylated to the active triphosphate analog. When
compared with cytarabine as a potent inhibitor of DNA synthesis [40], CP-4055 also
transiently inhibits RNA synthesis. Furthermore, the fatty acyl conjugation potentially
delayed inactivation to ara-U. CP-4055 is not a substrate for cytidine deaminase. CP4055 demonstrated cytotoxicity in solid tumor and leukemia cells in vitro and in vivo
[41]. CP-4055 was evaluated against a lymphoma cell line with deficient nucleoside
transport (5CEM-araC/C8) and was resistant to cytarabine. CP-4055 was able to kill a
high proportion of drug-resistant cells by apoptosis [42]. Further studies of CP-4055 in
human leukemia and lymphoma HL-60 and U937 cells demonstrated additive or
synergistic cytotoxic activity in combination with other anticancer drugs, such as
cloretazine, idarubicin, gemcitabine, irinotecan, and topotecan, [43].
Continued treatment with CP-4055 exhibited enhanced antitumor effect in human
leukemia and in solid tumor models in vivo. The elaidic acid derivative of cytarabine was
studied in phase 1 studies in patients with solid tumors, such as malignant melanoma,
ovarian cancer, and non-small cell lung cancer. The pharmacokinetic study in 34
patients demonstrated that at dose levels of >150 mg/m2 after 0.5-2 h intravenous
infusion, CP-4055 was well tolerated and remained in plasma for up to 5-10 hr [44]. CP4055 under the brand name ElacytTM has now moved to phase 3 trials (NCT01147939)
by Clavis Pharma in patients with late stage AML.
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Figure 5. Structure of elaidic acid-cytarabine conjugate (CP-4055).

The 2′-hydroxyl position of arabinose sugar in cytarabine was further explored for
functionalizing with fatty acids. We synthesized and evaluated the 2′-O and 5′-Omyristoyl and 2′,5′-dimyristoyl derivatives (Figure 6). As the cytotoxic mechanism of
cytarabine involves phosphorylation of 5′-hydroxyl into triphosphate, the effectiveness of
fatty acyl ester derivatives depends on the concentration of the parent drug delivered
intracellularly after hydrolysis and availability of 5′-hydroxyl group for phosphorylation
[45].
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Figure 6. Chemical structure of 5′-O-, 2′-O-monosubstituted and disubstituted
cytarabine derivatives.
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The 5′-substituted fatty acyl derivative of cytarabine was not able to inhibit
significantly the proliferation of leukemia cells (CCRF-CEM) even after 96 h at a
concentration of 1 µM. On the other hand, 2′,5′-dimyristoyl derivative of cytarabine and
2′-fatty acyl derivatives of cytarabine inhibited the growth of cancer cells by
approximately by ~36-76% at a concentration of 1 µM after 96 h incubation. 2′,5′Disubstituted derivative showed comparable activity to that of parent drug cytarabine
and physical mixtures after 96 h. Enhanced cytotoxic activity of 2′,5′-disubstituted
derivative after 96 h compared to that in 24 h indicate that the conjugate releases
cytarabine slowly and may behave as a prodrug for sustained delivery of the parent
nucleoside. Although the anticancer activity of the compound was only comparable to
that of cytarabine after 96 h, the sustained-release property may be beneficial.

2.3 Phosphate derivatives
The phosphate prodrug approach has been widely used with nucleoside drugs
[46]. Nucleosides are converted intracellularly into the monophosphate, diphosphate,
and triphosphate derivatives, respectively, before generating biological activities. The
monophosphorylation is generally the rate-determining step and thus delivery of
monophosphorylated nucleosides that bypass this step is highly desired. Cytarabine is
also converted into the triphosphate form before incorporation into nucleic acids. Thus,
various phosphate derivatives of cytarabine have been synthesized and evaluated as
discussed below.
Lipophilic phosphate prodrugs of cytarabine were designed to contain both the
phosphate and lipid (fatty chain) properties. The concept of using lipophilic nucleoside
17

monophosphate ester derivatives of cytarabine was proposed to bypass the first
phosphorylation step and circumvent tumor resistance associated with decreased
deoxycytidine kinase activity via kinase bypass. Furthermore, it was expected that
metabolic degradation by cytidine deaminase to be reduced. Finally, partial masking of
the phosphate charge and increased lipophilicity may allow higher intracellular levels of
the parent analog [47,48,49].
Initially, it was expected that cleavage of the prodrug moiety was due to the
action of phosphodiesterase; however, it was subsequently demonstrated that the
release of the parent drug occurs via successive two-carbon degradation via oxidation
in peroxisomes [50]. The investigations led to discovery of the stearyl phosphate diester
of cytarabine (cytarabine ocfosfate, YNK01) (Figure 7) [51]. Further clinical evaluation of
cytarabine ocfosfate showed enhanced stability and higher half-life when compared with
cytarabine and showed great promise for oral administration [52,53,54]. A phase 1/2
study demonstrated that 15.8% of the total dose was absorbed and metabolized to
cytarabine and AraU [55]. Cytarabine ocfosfate was approved in 1992 [56] in Japan by
Nippon Kayaky under license from Yamasa Shoyu for use in patients with adult acute
nonlymphocytic leukemia and myelodysplastic syndrome [57].
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Figure 7: Chemical structure of cytarabine ocfosfate.

Among other phosphate derivatives, the 5′-protected phosphate triester
derivatives of cytarabine have been also evaluated as prodrugs. Gouy et al. synthesized
mixed phosphate triester derivatives of cytarabine [58] (Figure 8), which were expected
to release intracellularly cytarabine monophosphate after esterase- and
phosphodiesterase-mediated hydrolysis, respectively (Figure 9).

Figure 8. Chemical structures of mixed phosphate araC prodrugs.

Whereas other phosphotriester derivatives with other nucleoside drugs, such as
AZT containing S-acyl-2-thioethyl (SATE) phenyl pronucleotides, have shown
improvement in activity versus their parent nucleosides, these protected phosphate
triester derivatives showed reduced activity against the leukemia cell lines when
compared with that of cytarabine. The reduced antitumor activity observed with
phosphotriester derivatives of cytarabine was assumed to be a result of the limited
19

cellular uptake, a reduced hydrolysis to the nucleoside monophosphate, extracellular
hydrolysis to nucleoside monophosphate, or an unexpected decomposition mechanism
that hampered the intracellular formation of the 5′-mononucleotide (araCMP).

Figure 9. Possible mechanism of hydrolysis of a phosphotriester prodrug of cytarabine
into a monophosphate derivative.
To compare the hydrolysis of phosphotriester derivatives of nucleosides [58],
three derivatives, cytarabine phosphotriester derivative, AZT phosphate prodrug, and
snake venom phosphodiesterase (SVP)-substrate (p-nitrophenyl thymidinyl phosphate),
were tested in presence of SVP (snake venom phosphodiesterase), a representative for
the type I phosphodiesterase enzyme family at 37 °C. The hydrolysis led to the
formation of the corresponding nucleoside 5′-monophosphate (Figure 9) with half-lives
of 4.6 h for cytarabine derivative, 53 min for AZT derivative, and 43 min for p-nitrophenyl
thymidinyl phosphate. Thus, 2′-deoxynucleotides were hydrolyzed faster than the
corresponding ribonucleotides, and the araC metabolite appeared to be a poor
20

substrate for SVP when compared to AZT or thymidine. These data suggest that a slow
hydrolysis to cytarabine monophosphate contributes to reduced antitumor activity.
Phosphoramidate derivatives of cytarabine were also shown to have reduced
anticancer activity when compared with cytarabine. For example, a nitrofuran
phosphoramidate derivative (Figure 10) reported by Tobias et al. showed reduction in
anti-proliferative activity when compared to that of cytarabine [59].

Figure 10. Chemical structure of a cytarabine nitrofuran phosphoramidate.

Phosphoramidate derivatives of cytarabine metabolite 2-β-D-arabinouridine
(AraU) (Figure 11) were evaluated by Mehellou et al. [60]. The rationale for this study
was to determine whether phosphorylation of AraU can activate the inactivate
metabolite. Thus masked phosphate prodrug was synthesized for intracellular delivery.
The compounds found to have reduced activity when compared with AraU. Hydrolysis
studies in cell extract by NMR showed the reduced activity of phosphoramidate
derivatives to hydrolysis because of the stability of P-N bond to hydrolysis.
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Figure 11. Chemical structure of AraUphosphoramidates.

In general, the biological activities of synthesized fatty acid, amino acid, and
phosphate conjugates depended upon the mechanism and ease of intracellularly
released cytarabine or monophosphate derivative. The phosphorylation process occurs
on the 5′-OH group of the arabinose sugar. Prodrug strategies that used either the
substitution at 4-amine group of cytosine base or the protected 5′-monophosphate
derivatives have resulted in compromised activities against various cancers.

3. Delivery Systems
The drugs, which have poor solubility, low cell permeability, fast metabolism and
elimination, or require continuous dosages for a longer period of time, could be
encapsulated in a protected sheath or fast delivery vehicle without any covalent or
chemical modification in drug structure. Various vehicles, sheaths, particles or systems
have been introduced as drug delivery systems for improving the delivery of drug
molecules to target organ in required dosages. Some of drug delivery systems or
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vehicles include nanoparticles, polymers, hydrogels, organogels, niosomes, and
liposomes.
The nucleoside drugs are polar compounds and have generally low membrane
permeability. A number of delivery systems evaluated with anticancer nucleoside drugs
have been reviewed recently [61,62].
Cytarabine is a highly polar water soluble nucleoside. Various systems have
been investigated for encapsulation and targeted delivery of cytarabine. The selection of
cytarabine delivery systems [63] depends upon their encapsulating capacity. Some
include nanoparticles, hydrogels, chitosan, niosome vesicles of tween 20, and
liposomes. Liposomal cytarabine was approved by the FDA for the treatment of
lymphomatous meningitis [64].

3.1 Hydrogels
Hydrogels are biomaterials consisting of a polymer matrix with a high water
retention capacity. The hydrogels are capable of encapsulating the hydrophilic drugs.
Sustained release of the drug depends on the polymer matrix constitution. The
hydrogels have application as biomaterials since they have similarity in physical
properties, such as water contents, soft consistency and low interfacial tension, to those
of natural tissues in biological systems [65]. The encapsulation of hydrophilic drugs
such as nucleoside analogs with hydrogels would be easy and loading could be
expected higher compared to other polymers. On the other hand, the strong interaction
among the polymer and drug would hinder the release.
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Cytarabine has been studied with HEMA (2-hydroxyethyl methacrylate) [66] and
HEMA copolymerized with acrylamide [67]. The study showed that the rate and total
time of cytarabine release from the copolymer (hydrogels) can be partially modulated by
varying the amount of monomer composition and degree of cross linking of the gels.
Even though, hydrogels have not been completely successful for delivery of cytarabine,
more studies with different polymer compositions can be used in finding the balanced
system for drug encapsulation as well as sustained release.

3.2 Liposomes
Liposomes or lipid capsids have been important vehicles for the delivery of a
number of drugs [68]. The liposomes are lipophilic systems and can pass the cell
membranes easily [69]. They possess unique pharmacokinetic characteristics because
of their nanometer size (ranges in mean diameter from 50 to 250 nm) as systemically
administered vesicles [70]. These unique characteristic properties allow clearance via
the reticuloendothelial system, which leads to a relatively long systemic circulation time,
and hepatic and splenic distribution. Furthermore, the liposomes exhibit preferential
extravasation and accumulation at the site of solid tumors due to increased endothelial
permeability and reduced lymphatic drainage in these tissues [71]. The increased
endothelial permeability has been defined as enhanced permeability and retention effect
[72].
Thus, liposomal delivery is a means to modify the pharmacokinetic and
pharmacodynamic properties of anticancer agents [73], improving pharmacological
properties, and reducing or modulating their toxicity profile [74]. Polar drugs once
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encapsulated inside the liposomes are transported across the membranes by facilitated
mechanism of liposome capsid. Liposomal cytarabine formulation has been studied with
different liposomal compositions and hybrid systems with polymers [75].
The cytarabine encapsulated liposome has been studied with thermosensitive
hydrogels [76]. The hydrogel was based on the biodegradable chitosan and βglycerophosphate (C-GP) that are thermosensitive and act as a thermal trigger to
regulate the drug release from encapsulation. Combining of liposomes with C-GP
hydrogel system gave the advantages of more sustained release of cytarabine along
with a higher stability of the hydrogel-liposome system compared to liposome alone.
The investigators suggest hydrogel system is appropriate for controlled and sustained
release of cytarabine.
Cytarabine crosses the blood-brain barrier only to a limited extent after rapid i.v.
administration. Liposomes with encapsulated cytarabine showed enhanced half-life and
were found to be suitable for the treatment of lymphomatous meningitis. The formulation
has been approved for the treatment of lymphomatous meningitis under the brand name
(DepoCyt®) [77]. DepoCyt® formulation is prepared by encapsulation of a sterile
suspension of cytarabine into multivesicular lipid based polymeric liposomal particles
composed of cholesterol, triolein, dioleoylphosphatidylcholine (DOPC) and
dipalmitoylphosphatidylglycerol (DPPG). DepoCyt® is administered as intrathecal
injection in cerebrospinal fluid for the treatment of neoplastic meningitis as a sustainedrelease formulation that maintains cytotoxic concentrations of cytarabine in
cerebrospinal fluid for more than 14 days following a single injection [78,79].
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Cytarabine has been used in the combination with anticancer drugs for
synergistic antitumor activity. The combination of anticancer drugs as a cocktail is now
commonly used clinically in cancer chemotherapy. Alternatively, two or more drugs can
be encapsulated in the liposomes to enhance the delivery. The combination of
cytarabine with daunorubicin HCl (a DNA intercalator) in 5:1 ratio in a liposomal
formulation (cytarabine/daunorubicin HCl liposome injection) has been used by
intravenous infusion for synergistic therapy in the leukemia treatment as CPX-351 [80].
The liposome membrane is composed of distearoylphosphatidylcholine (DSPC),
distearoylphosphatidylglycerol (DSPG), and cholesterol in a 7:2:1 molar ratio. The
liposomal formulation (CPX-351) demonstrated enhanced therapeutic activity in
preclinical tumor models [81] and promising anticancer activity in a phase I clinical trial
in patients with hematological malignancies [82,83].
The substituted derivatives of cytarabine have also been encapsulated in
liposomes to improve the delivery and anticancer activity. Schwendener et al. studied
the encapsulation of N4-fatty acyl derivatives in liposomes and evaluated their potency
compared to cytarabine liposomes [84]. The lipophilic N4-hexadecyl cytarabine (a
potent derivative among N4-fatty acyl derivatives) was encapsulated in liposomes and
evaluated in a cologenic assay with HL-60 cells showing comparable activity with
cytarabine. On the other hand, the liposomal formulation showed higher cytotoxicity in
cytarabine resistant cell line compared to that of parent cytarabine [85]. The cellular
uptake of liposomal cytarabine derivative was found to be five times more than
cytarabine [86]. Similarly among other derivatives of cytarabine N4-octadecyl cytarabine
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also showed a similar behavior. After intravenous injection, the liposomal formulation
showed longer plasma half-life compared to cytarabine [87,88].

3.3 Nanoparticles
Nanometer size particles have higher delivery through enhanced permeability to
the tumor sites [89]. Drugs attached or encapsulated are delivered at higher
concentrations to the site of action and are protected from fast excretion [90]. The
polymeric nanoparticles have been extensively investigated for the delivery of various
drugs [91,92].
Rukmani et al. investigated the methacrylic acid polymeric nanoparticles
encapsulation of cytarabine [93]. Detailed morphological analysis of nanoparticles and
further in vivo study of hematological parameters after administering CTH nanoparticles
continuously for 9 days to tumor bearing mice showed improvement in lifespan of
leukemia mice by the formulation when compared to cytarabine alone. The
nanoparticular cytarabine formulation was able to restore the altered physiological
parameters of leukemic mice to the normal levels and found to have improved
pharmacokinetics profile and prolonged the lifespan of mice with increased white blood
cells count that make the nanoparticle a potential carrier for the cytarabine.

3.4 Other Delivery systems
Among other systems that can serve as delivery vehicles, the natural or artificial
polymers/molecules that are biocompatible have been evaluated to improve the delivery
of the drug. Some systems include chitosan [94] and niosome vesicles [95] of tween-20
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and tween-80 [96,97]. With these systems little success has been made in getting the
final applicable system because of insufficient release of the drug from the conjugates.
In conclusion, among the delivery systems evaluated for application of
cytarabine, liposomal formulation has been successful in increasing the half-life and
found application in treatment of lymphomatous meningitis. The other systems have
shown promising improvement in delivery and require more systemic study for final
application.

4. Conclusion
Cytarabine, a polar nucleoside antileukemia drug with limited plasma stability and
cell permeability, has been extensively evaluated by using prodrug and delivery
systems. The prodrug attempts to improve delivery to target tissues, plasma stability,
and therapeutic effect have been successful in generation of new drug conjugate
molecules. Based on these concepts, a number of prodrugs and formulations were
designed for cytarabine. Prodrug strategies included conjugation with fatty acids, amino
acids, and substituted-phosphate derivatives of cytarabine. The activities of these
conjugates were dependent on the rate of hydrolysis, cellular uptake, and resistance to
cytidine deaminase. Among the prodrugs amino acid derivative ValCytarabine and fatty
acid derivative CP-4055 (under Phase II trials) are being evaluated for the treatment of
leukemia and solid tumors, respectively. Among lipophilic phosphodiester derivatives,
cytarabine ocfosfate was approved for leukemia treatment. Furthermore, many delivery
systems for improving cellular permeability, encapsulation, and the sustained release of
cytarabine have been evaluated. Some include hydrogels, liposomes, niosomes,
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nanoparticles, and polymers. The liposomal-cytarabine formulation (DepoCyt®) has
been approved for the treatment of lymphomatous meningitis. Both prodrug and delivery
systems have been effective in improving the biological profile of cytarabine. These
approaches provide insights for designing prodrugs or delivery systems for other
anticancer nucleoside drugs. Future investigations are required to generate additional
prodrugs and delivery systems with optimal biological activity and delivery. Furthermore,
a combination of using an optimal cytarabine prodrug with an appropriate delivery
system or using cytarabine or cytarabine prodrugs in conjunction with different
anticancer regimens and/or delivery systems may be needed to explore further
applications of these strategies in anticancer research.

5. Expert Opinion
The concept of prodrug has been successfully used in improving the delivery,
stability and pharmacological properties of drugs. The prodrug design is based on direct
molecular changes on the drug to generate a dormant compound with appropriate
physicochemical properties and desired biological activities. In case of nucleoside
analogs, the prodrug designing concept is also used to bypass rate-limiting metabolic
process by delivering nucleotides. It is not always easy to predict whether the dormant
prodrug will be successful in generating desired properties. As shown with many
designs for cytarabine prodrugs, modulating higher stability and better release in target
tissues still remain a major challenge. Designing diverse number of prodrugs has
allowed the discovery of compounds with optimal stability and release properties.
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Nucleoside analogs have sugar and base moieties. The conjugation at
appropriate positions is required for designing optimal prodrugs. Cytarabine has an
arabinose sugar with three hydroxyl groups and a base with a free amino group. These
functional groups generate high polarity and a limited cellular uptake. Furthermore,
some of the functional groups, such as 4-amino and 5′-hydroxyl groups, are critical in
stability and activation of the nucleoside, respectively. Cytarabine is inactivated by
deamination of the base. Thus, some of the methods used for designing prodrugs of
other anticancer or antiviral nucleosides may not be used here since additional care
must be taken to prevent deamination. On the other hand, cytarabine is activated by
conversion into nucleotides through phosphorylation at 5′ position. The designed
prodrugs of cytarabine used the attachment of functional moieties at either the amino
group of the base or 5′-hydroxy group arabinose sugar. The initial modifications used
the fatty acids and different amino acids to improve the delivery and protection from
deamination.
The rationale behind 4-N modification with introducing the amide group and bulky
fatty acids and amino acids was to block enzyme-mediated deamination into uridine.
Although the stability of the compounds were enhanced by reducing deamination,
modifications at N4 position led to reduction of activity of the compounds compared to
the parent analog. A less unhydrolyzable amide and the presence of a bulky group
(amino acids alone and/or with fatty acid) at position 4 made the parent drug less active
possibly due to the presence of steric hindrance at the base during incorporation in
nucleic acids. Thus, for improving the stability with N-4 substitution may not generate
prodrugs with optimal biological properties.
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Alternatively, introduction of functional moieties at 5′-OH involved with
hydrolyzable ester groups gave products with improved pharmacological properties.
The 5′-fatty acid derivative (ElacytTM) is under phase 3 clinical trials for anticancer
studies (NCT01147939) by Clavis Pharma.
Furthermore, prodrugs with a substituted phosphate group were expected to
enhance biological activity by bypassing the first intracellular rate-limiting
phosphorylation step. A simple lipophilic phosphate diester prodrug, cytarabine
ocfosfate, was approved in 1992 for leukemia treatment. However, the
phosphoramidate derivatives with stable P-N bond showed reduced antiproliferative
activity in most of the cancer cells including leukemia and solid tumor lines. Thus, less
stable phosphoester prodrugs are preferred to amidate counterparts for designing the
next generation of lipophilic phosphate prodrugs of cytarabine.
Less research has been carried out on conjugation of cytarabine with hydroxyl
groups at 2′ and 3′ positions. It appears that substitution at 5′-position with fatty acids
alone is beneficial in generating higher lipophilicity and cellular uptake, but may slow
down the metabolic phosphorylation of cytarabine. Alternatively, it may be possible to
design prodrugs with masked phosphate at 5′-position and lipophilic chains at 2′ or 3′
positions. It remains to be seen whether this strategy can combine the benefits of both
approaches.
Owing to limited cellular uptake of cytarabine, noncovalent methods using
delivery systems or vehicles were expected to show great promise. These strategies will
protect the chemical integrity of cytarabine and the compound is delivered in an intact
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form. The encapsulation into protected sheaths like polymers, liposomes, hydrogels,
and niosomes were expected to provide advantage of membrane transportation and
continuous availability in the plasma over time. Among the evaluated delivery systems,
the liposomal formulation was successful in enhancing the cytarabine half-life and
treatment of lymphomatous meningitis. The hydrogels and niosomes were able to
entrap polar cytarabine but the release from these systems remained slow due to strong
interaction of drug with the sheath. The future studies need to focus on more
optimization of delivery sheaths particularly hydrogel surfaces and nanoparticles to
generate controlled or sustained release and appropriate balance of encapsulation and
release properties.
It remains to be determined whether an optimal cytarabine prodrug or those
under evaluations (e.g., ElacytTM) can be combined with promising delivery systems
such as liposomes. Furthermore, cytarabine is also used in combination with other
anticancer drugs in treatment of patients. Further studies are required to determine
whether combination of cytarabine prodrugs with other anticancer agents or using
anticancer cocktails containing cytarabine prodrug or cytarabine with an appropriate
delivery system can have any beneficial therapeutic effect in treatment of cancer
patients.
In summary, design of cytarabine prodrug derivatives and use of delivery
systems have generated prodrugs or formulations that have optimal anticancer activity,
stability, or delivery. The exploration of inactive prodrugs or not optimal delivery systems
provided deep understanding of the underlying factors responsible for inactivity or
incompatibility in formulation that led to the development of first generation of products
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approved by FDA. Further improvement in design, modification in the drug molecule, or
delivery sheath may lead to the second generation of compounds with broader
applications. The same path may inspire the investigators to design more optimized
anticancer nucleosides and other anticancer agents using the knowledge gained here.
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